AdvaMed Urges Biden Administration To Use CHIPS To Prioritize Patient Care

Now that the CHIPS and Science Act is law, AdvaMed wants the Biden administration to use it to ensure device makers get the semiconductor chips they need for their products while preventing the US from facing another shortage of the essential components, as experienced during the pandemic.

Microchip USA
• Source: Shutterstock

When President Joe Biden signed the CHIPS and Science Act into law in August it was one of the few pieces of legislation embraced across the aisle in a hyper-partisan climate. CHIPS aimed, in part, to address the dire shortage of semiconductors – computer chips essential to running everything from household appliances to lifesaving medical devices – that US industry faced.

Support for the legislation only increased during the pandemic when supply chain shortages highlighted the risk of relying on overseas...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

US FDA Unveils Plans To Consolidate Support Services

 

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

MDUFA VI Launches With Public Meeting, Call For Comments

 
• By 

Preparations for the reauthorization of the Medical Device User Fee Amendments for 2028-2032 are underway, with the US FDA announcing a public meeting for 4 August. After negotiations with industry and other stakeholders, a draft agreement is due to Congress by 15 January 2025.